Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit
Update: 2025-11-04
Description
Pfizer and Novo Nordisk are locked in a high-stakes battle for Metsera, a biotech startup developing promising obesity drugs. Pfizer accuses Novo of using a $9 billion bid to stall Metsera's treatments, while Novo rejects these claims. The dispute centers around Metsera's potential game-changing monthly shot, which could bring in up to $5 billion in annual sales. The case is now heading to court in Delaware, with investors and patients eagerly awaiting the outcome.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
